Government
What Is the Opioid Crisis and Did Anyone Go to Jail?
More Americans have died from opioid overdoses since 1999 than in all US wars combined. The epidemic was knowingly created by a pharmaceutical company. Its owners profited enormously. Almost none of them went to prison.
This is one of the most consequential corporate crimes in American history — and one of the clearest examples of how wealth translates into legal protection.
How Purdue Pharma Created a Crisis
In 1996, Purdue Pharma — a private company owned by the Sackler family — launched OxyContin, an extended-release version of oxycodone.
The marketing campaign was sophisticated and deliberately misleading. Purdue trained sales representatives to tell doctors that OxyContin was less addictive than other opioids because of its extended-release formulation. Internal documents later revealed in litigation showed the company knew this claim was false — the drug was highly addictive, and its abuse potential was well understood internally.
Purdue paid doctors to prescribe OxyContin through speaking fees and other arrangements. It pushed for expansion of opioid use into non-cancer chronic pain patients — a vast market that prior medical norms had treated cautiously with opioids because of addiction risk.
The FDA approved OxyContin based on inadequate clinical evidence. Regulators at the agency responsible for approving the drug subsequently took positions at or benefiting the pharmaceutical industry.
The Three Waves
The opioid epidemic is now understood as three overlapping waves:
Wave 1 (1990s-2010): Prescription opioid addiction. Millions of patients given OxyContin and other prescription opioids became physically dependent. Deaths from prescription opioid overdose rose sharply through the 2000s.
Wave 2 (2010-2013): As prescription monitoring programs tightened and OxyContin reformulated to be harder to abuse, addicted patients who could no longer get prescriptions turned to heroin — cheaper and more available. Heroin overdose deaths spiked.
Wave 3 (2013-present): Illicit fentanyl, manufactured primarily in China and Mexico, entered the illicit drug supply. Fentanyl is 50-100 times more potent than morphine. It began appearing mixed into heroin without users' knowledge. Then into cocaine. Then into counterfeit pills made to look like prescription oxycodone. Drug users who thought they were taking familiar substances were actually taking fentanyl. Deaths exploded.
The fentanyl wave is the deadliest phase. Approximately 80,000-110,000 Americans die from overdoses each year in recent data, the vast majority involving fentanyl.
The Accountability Failure
Purdue Pharma paid approximately $8 billion in settlements and pleaded guilty to federal criminal charges. The company was dissolved in bankruptcy.
The Sackler family personally extracted approximately $11 billion from Purdue before its bankruptcy — much of it transferred to overseas accounts after litigation began. In the bankruptcy proceedings, they negotiated a settlement providing billions in payments in exchange for civil immunity — meaning individuals and states who were harmed couldn't sue them personally.
The Supreme Court struck down the immunity provisions in 2024 (Harrington v. Purdue Pharma), holding that non-debtor parties (the Sackler family members who hadn't personally filed for bankruptcy) couldn't use bankruptcy proceedings to buy immunity from civil suits they hadn't themselves filed.
Criminal prosecution of Sackler family members: none. Individual family members were not charged with crimes related to their company's role in the epidemic.
The contrast with other criminal contexts is stark: low-level drug users who sell small amounts of opioids face federal mandatory minimums of 5-10 years. The people who created the market for addiction, who knowingly misled doctors and patients about addiction risk, who extracted billions in profits — face civil settlements and no prison time.
Whether this represents justice is not a complicated question.
What Changed
States have enacted opioid settlement requirements. Purdue's bankruptcy produced $6+ billion in settlement funds distributed to states for addiction treatment and prevention.
The DEA has significantly tightened prescription monitoring. Electronic prescription databases have made "doctor shopping" harder. Prescriptions for opioids have declined dramatically since their 2012 peak.
But the addiction population created in the 1990s-2000s has largely transitioned to illicit fentanyl. Reducing prescription opioid access didn't reduce the epidemic — it transformed it into a more lethal phase.
The public health response that evidence supports: expanded naloxone (overdose reversal medication) access, expanded medication-assisted treatment (methadone, buprenorphine) without the regulatory barriers that currently limit it, harm reduction programs (clean needles, fentanyl test strips), and treatment funding from the opioid settlements.
Mortality rates have begun declining in some states with robust harm reduction programs. The tools exist. The question is whether the political will to use them — which requires treating addiction as a health issue rather than a moral failure — is sufficient.